🔥Telegram İfşa

Did you know that Type 1 diabetes (T1D) is an autoimmune disease? This #AutoimmuneDiseaseAwarenessMonth, we are raising awareness for people living with T1D and other autoimmune diseases. Learn more about T1D on our website: bit.ly/3XfSwMU

In a recent episode of the Diabetech podcast, our CEO, Jonathan Rigby, talks about his experience living with T1D and how the Sernova team is working to advance our Cell Pouch bio-hybrid organ through the clinic. Watch the interview here: bit.ly/3F8McAw

Perry Calias, PhD, has joined Sernova as Chief Development Officer and Head of R&D. Read our press release for more on how he will leverage his 20+ years of biopharma experience to help us advance our Cell Pouch bio-hybrid organ through the clinic: bit.ly/3DvkH3O

With the help of insulin, the body turns food into energy by allowing glucose into cells. In Type 1 diabetes (T1D), the immune system attacks insulin-producing cells, requiring daily insulin therapy. Learn more from the #T1DKidsCorner on our website: bit.ly/40Dgxyo

In addition to Type 1 diabetes, we are also evaluating our technology in hypothyroidism. Our Investigational New Drug (IND) application for this program was cleared by the United States Food and Drug Administration (FDA) in March. Visit our page for more: bit.ly/4jDQCz3

Our CEO, Jonathan Rigby, recently joined Chris O’Brien on the Biorasi Few & Far Between podcast to discuss the future of treating Type 1 diabetes (T1D) and the potential of our Cell Pouch bio-hybrid organ. Listen via the episode linked below.

Our platform merges our bio-hybrid organ with therapeutic cells to correct the underlying deficiencies of hormones, proteins, and other factors caused by T1D, hypothyroidism, and other chronic diseases. Check out our website for more on Our Focus: bit.ly/41shB9R

Today we shared a positive update on the ongoing Phase 1/2 clinical trial evaluating the safety and tolerability of islet transplantation into our Cell Pouch™ Bio-Hybrid Organ for the treatment of #Type1Diabetes (#T1D). Learn more: bit.ly/3FPNWiB

For over 100 years, advances in treating Type 1 diabetes (T1D) have transformed lives, yet the need for less burdensome solutions remains. With our Cell Pouch bio-hybrid organ we aim to give people their lives back and ease the burden on T1D. Learn more: bit.ly/4aLTohB

Our team has evolved over the last several months – check out our website to learn about our combined expertise and experience which we are leveraging to drive the clinical advancement of our Cell Pouch bio-hybrid organ: bit.ly/42700Dn

For kids with #Type1Diabetes, blood sugar monitoring is essential to maintain health during daily activities. This can be done using a fingerstick device or a small, continuous monitor worn on the body. Learn more by visiting our #T1DKidsCorner: bit.ly/40Dgxyo

Our Cell Pouch Bio-Hybrid Organ will be highlighted during a panel discussion at the Alliance for Regenerative Medicine (ARM)’s Cell & Gene Meeting on the Med in Rome. Read our press release to learn more: bit.ly/4lytz9T

With our Cell Pouch bio-hybrid organ, we aim to establish an environment in the body that supports the long-term survival and function of therapeutic cells. Learn more on our website: bit.ly/41shB9R

Our CEO, Jonathan Rigby, was recognized as part of The Medicine Maker's 2025 Power List. His journey with T1D fuels his drive to be an advocate for the T1D community while also advancing the Cell Pouch Bio-hybrid Organ as a potential functional cure. Congratulations, Jonathan!

During #WomensHealthMonth, we aim to raise awareness for how women experience life with type 1 diabetes (T1D). Learn more by reading about the gender gaps in T1D care: bit.ly/4iHbOCz

This #MothersDay, we celebrate the strength, love, and resilience of moms raising kids with #T1D. We see you. We thank you. 💐 Tag a T1D mom who deserves extra love! #Type1Diabetes

Today we shared new positive interim data from the ongoing Phase 1/2 clinical trial evaluating the Cell Pouch Bio-hybrid Organ in combination with human donor islet cells. Read our press release for details: bit.ly/4dlcIni

Don't miss our CEO, Jonathan Rigby, and clinical advisor, Dr. Robert Gabbay, discuss the past, present, and future of treating type 1 diabetes as part of Technology Networks' Innovations in BioPharma 2025 online event. Register here: bit.ly/3S6cwP9

On #ClinicalTrialsDay, we recognize the selfless dedication of patients, researchers, and the entire team who makes our ongoing Phase 1/2 clinical trial possible. Their commitment fuels the progress behind the advancement of our Cell Pouch Bio-hybrid Organ.

We are proud to announce the formation of our Clinical Advisory Board. This globally respected group of experts will provide critical guidance as we advance our Cell Pouch Bio-hybrid Organ for people with type 1 diabetes. Explore the board: sernova.com/press_releases…